CJC-1295 Ipamorelin: Frequently Asked Questions

Definitions and Overview

What are CJC-1295 and ipamorelin?

CJC-1295 is a synthetic GHRH analog studied for sustained GH release via albumin-bound half-life extension. Ipamorelin is a selective GHRP — a five-residue synthetic peptide that binds GHS-R1a for pulsatile GH secretion with minimal cortisol, prolactin, or gonadotropin side effects in published rat and swine studies ^[3]. Combined, they operate on two distinct receptor arms of the GH axis.

What is CJC-1295 ipamorelin good for?

The CJC-1295/ipamorelin blend has been studied in preclinical models for GH pulsatility and IGF-1 elevation ^[1], bone mineral content and longitudinal growth ^[4][9], periosteal bone formation rate under glucocorticoid stress ^[8], gastrointestinal motility restoration via GHS-R1a agonism ^[10], and sleep architecture via ghrelin-receptor mechanisms ^[12]. No FDA-approved indication exists for either compound.

Why are CJC-1295 and ipamorelin used together?

CJC-1295 amplifies the GH baseline through GHRH receptor agonism while ipamorelin triggers acute GH pulses via ghrelin-receptor binding. The two axes act supraadditively: a near-threshold GHS dose plus a maximally effective GHRH dose produced greater-than-additive GH release across five species in published research ^[13].

What is CJC-1295 ipamorelin good for?

See above — bone growth, GH/IGF-1 axis elevation, GI motility, and sleep-architecture modulation are the primary studied endpoints. No clinical indication is approved.

What are peptides and what is peptide therapy?

Peptides are short amino acid chains — below 50 residues — that act as signaling molecules by binding specific receptors. Peptide research explores receptor-specific activity in biological models. CJC-1295 is a 29-residue GHRH-analog and ipamorelin is a 5-residue GHS-R1a agonist — two distinct peptide classes acting on distinct receptor targets on the GH axis.

Is CJC-1295 an HGH-releasing hormone?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — it mimics endogenous GHRH by binding pituitary GHRH receptors to amplify GH secretion. It does not administer GH directly; it stimulates the pituitary to release endogenous GH. In human studies at 60–90 µg/kg subcutaneous, mean GH rose 46% and IGF-1 rose 45% at one week ^[1].

Pharmacokinetics and Timing

What is the half-life of CJC-1295 and ipamorelin?

CJC-1295 without DAC: below 30 minutes (DPP-IV-limited, analogous to native GRF(1-29), which has a half-life under 13 minutes ^[16]). CJC-1295 with DAC: approximately 6–8 days (albumin-bound) ^[2]. Ipamorelin: approximately 2 hours in rodents — no validated human half-life data are published ^[7].

What is the difference between CJC-1295 with DAC and without DAC?

Drug Affinity Complex (DAC) modification extends CJC-1295 half-life to approximately 6–8 days by forming a covalent in vivo bond with serum albumin via the maleimidopropionamide moiety. Without DAC, CJC-1295 retains amino acid substitutions resisting DPP-IV but lacks albumin binding, producing a much shorter half-life of approximately 30 minutes. The DAC form produced a 4-fold increase in GH AUC over 2 hours compared with native hGRF(1-29) in rat studies ^[2].

How long do CJC and ipamorelin take to work?

CJC-1295 produced sustained GH elevations within hours of injection in human trials; IGF-1 elevation was confirmed at one week ^[1]. Ipamorelin's acute GH pulse peaks approximately 15–30 minutes post-injection in rodent models based on GHS-R1a pharmacodynamics. Ipamorelin human time-course data have not been published.

Should CJC-1295/ipamorelin be taken fasted or with food?

Research protocols typically specify fasted administration. Food intake raises insulin, which triggers somatostatin release, which blunts GH pulse amplitude. In a 5-day fasting study in men, GH pulse frequency increased from 5.8 to 9.9 pulses per 24 hours and 24-hour GH concentration nearly tripled (p=0.0002), with reduced insulin establishing somatostatin suppression as the mechanism ^[11]. Direct CJC-1295/ipamorelin timing trials in fasted versus fed human subjects have not been published.

How often should you inject CJC ipamorelin?

Published research protocols for CJC-1295 with DAC used once-weekly or less frequent subcutaneous injection consistent with its multi-day half-life ^[1]. Ipamorelin protocols in animal models specified 1–3 daily pulses ^[4][8][10]. Human combination injection frequency protocols have not been published in peer-reviewed literature.

Safety and Side Effects

What are the bad side effects of CJC-1295 and ipamorelin?

In CJC-1295 clinical study participants: injection-site reactions, transient facial flushing, peripheral edema, and mild headache. No serious adverse events attributed to CJC-1295 were reported in published healthy-subject Phase I/II-context trials. Ipamorelin Phase I data confirmed no cortisol, ACTH, FSH, LH, or prolactin elevation even at 200-fold above GH ED50 ^[3]. The broader secretagogue class literature reports mild glucose elevation and insulin resistance as recurring signals with oral GHS agents.

What are the potential side effects of CJC-1295?

Phase I/II-context trials reported injection-site reactions, peripheral edema, headache, and transient glucose changes at high doses. Ipamorelin trials noted minimal cortisol or prolactin elevations compared with earlier GHRPs. GHS-independent adipogenic effects (increased body fat and leptin in GH-intact mice) were observed with ipamorelin in one mouse study ^[19] — a finding not yet characterized in human data.

Does CJC-1295 raise testosterone?

CJC-1295 acts on the GHRH/GH/IGF-1 axis; published clinical trials did not report significant changes in testosterone, LH, or FSH compared to baseline. Ipamorelin's selectivity data in rat and swine models confirmed no FSH or LH elevation at 200-fold above GH ED50 ^[3]. No CJC-1295 or ipamorelin mechanism for testosterone elevation is characterized in published literature.

Does CJC-1295/ipamorelin cause cancer?

No published trial in healthy subjects attributed tumor development to CJC-1295 or ipamorelin. IGF-1 elevation is a theoretical oncologic concern; published CJC-1295 human trials reported no tumor-related events ^[1][6]. Epidemiological data link elevated IGF-1 with increased cancer risk; preclinical ipamorelin tumor-model data are limited. This theoretical concern has not been resolved in controlled long-term human data.

Do growth hormone secretagogues increase tumor growth risks?

IGF-1 elevation is a theoretical oncologic risk due to IGF-1's anti-apoptotic and proliferative properties. However, published CJC-1295 human trial data in healthy subjects showed no tumor-related events ^[1][6]. The Tausendfreund 2024 systematic review of GH therapy in aged patients with comorbidities found no severe adverse events including no oncological events across eight RCTs ^[21]. The Endocrine Society 2023 statement did not identify tumor growth as a confirmed outcome in GHS trials but did not dismiss the theoretical concern ^[20].

Is CJC-1295 safe for women?

CJC-1295 Phase II clinical trials enrolled both male and female subjects; sex-stratified adverse event analysis was not published in the primary literature. Ipamorelin animal studies have not reported sex-dependent toxicity differences. Selectivity data confirming no FSH or LH elevation ^[3] holds across both sexes in published animal data.

Efficacy and Outcomes

Does CJC-1295 ipamorelin work?

CJC-1295 Phase II trials demonstrated statistically significant mean GH and IGF-1 increases versus baseline in healthy men ^[1]. Ipamorelin's GH-stimulating effects in rat and swine models were confirmed in the selectivity study ^[3] and in Phase I data. GHS synergy was confirmed across five species ^[13]. Combination human efficacy data in controlled trials do not exist in peer-reviewed literature.

Will CJC-1295/ipamorelin help with weight loss and muscle building?

In GH-deficient (GHRH-knockout) mice, CJC-1295 restored normal lean mass and subcutaneous fat mass ^[5]. In rats counteracting glucocorticoid-induced muscle loss, ipamorelin increased tetanic muscle tension ^[8]. MK-677 (an oral GHS class member) increased fat-free mass +1.1 kg in older human subjects over 12 months ^[17]. Direct CJC-1295/ipamorelin body composition data in healthy human subjects have not been published.

Does CJC-1295 ipamorelin cause weight gain?

In GH-deficient rodents, CJC-1295 produced weight normalization to normal ranges ^[5]. In GH-intact mice, ipamorelin produced modest adipogenic effects — increased relative body fat and elevated food intake via GH-independent mechanisms ^[19]. CJC-1295 in human trials did not produce significant weight changes at studied doses. IGF-1 elevation can promote anabolic partitioning in animal models.

How long does it take to see results from CJC-1295 and ipamorelin?

CJC-1295 Phase II trials showed IGF-1 elevation within 2 weeks; sustained for up to 28 days post-dose with the DAC form ^[1]. Bone growth and body composition endpoints in animal studies showed measurable changes at 4–8 weeks of sustained dosing ^[4][8][9]. Human combination outcome timelines have not been published.

Comparisons

What are the CJC-1295 ipamorelin vs sermorelin differences?

Sermorelin is the first 29 amino acids of GHRH (GRF(1-29)) without DPP-IV-resistant substitutions or DAC albumin-binding; its half-life is below 30 minutes. CJC-1295 (DAC form) has an approximately 6–8-day half-life ^[16][2]. Published head-to-head human comparison studies are absent. Sermorelin produces acute short-lived GH pulses; CJC-1295 DAC provides sustained tonic GH baseline elevation. Some protocols have used sermorelin + ipamorelin as a lower-cost substitute for CJC-1295 + ipamorelin.

Which is better: MK-677 or CJC-1295 ipamorelin?

MK-677 is an oral ghrelin mimetic with a 24-hour half-life and continuous GH/IGF-1 elevation; CJC-1295/ipamorelin is injectable and produces pulsatile GH release preserving circadian rhythm. MK-677 (25 mg/day) elevated mean 24-hour GH 97% ± 23% in 32 elderly subjects ^[14]. Published direct comparison studies between MK-677 and CJC-1295/ipamorelin do not exist. The mechanisms are related (both involve GHS-R1a agonism for ipamorelin and MK-677) but the pharmacokinetic and administration profiles differ substantially.

How does CJC-1295/ipamorelin differ from growth hormone injections?

Secretagogues stimulate the pituitary to release endogenous GH in a pulsatile pattern preserving the IGF-1 negative feedback loop. Exogenous rhGH bypasses pituitary regulation and suppresses endogenous secretion in animal models. The preserved feedback loop under secretagogue stimulation is the proposed self-limiting mechanism — when IGF-1 rises sufficiently, somatostatin increases and pituitary GH synthesis decreases.

Practical and Regulatory

How to reconstitute CJC-1295 ipamorelin 5mg?

Lyophilized peptide vials are reconstituted with bacteriostatic water in research settings. Standard reference protocols add BAC water slowly down the vial wall — not directly onto the lyophilized pellet — to avoid agitation-induced aggregation. Reconstituted solutions degrade via asparagine deamidation and should be stored at 2–8°C; degradation products may be 25–500-fold less potent than intact peptide.

Is CJC-1295/ipamorelin FDA-approved?

Neither CJC-1295 nor ipamorelin holds FDA approval for any human indication. Both appeared on FDA 503A/503B compounding restriction lists; as of December 2024 FDA PCAC briefing documents, CJC-1295 acetate forms were proposed not to be included on the 503A Bulks List. Neither compound has completed Phase III trials. For full regulatory status, see the About page.

Can CJC-1295/ipamorelin be combined with other peptides?

Published animal studies have explored combinations of GH secretagogues with BPC-157, TB-500, and the GHRH-analog class; human combination controlled data are sparse. Co-administration with tesamorelin (an FDA-approved GHRH analog) has not been formally studied in published literature — pharmacological redundancy on the GHRH-R axis is a mechanistic concern ^[18].

Can CJC-1295/ipamorelin be used alongside testosterone replacement therapy?

No published controlled trial has formally studied this combination. The GH axis (CJC-1295/ipamorelin) and the androgen axis (TRT) are pharmacologically distinct, suggesting no direct pharmacological interaction. A published human study of GHRP-6 + GHRP-2 + sermorelin in hypogonadal men on TRT showed IGF-1 elevation without serious adverse events ^[15].

Who is a candidate for CJC-1295 and ipamorelin research protocols?

Published Phase I/II trials enrolled healthy adults aged 21–60 with normal pituitary function and no active malignancy; protocols excluded subjects with diabetes, active cancer, or pregnancy. Subject selection criteria in published trials do not constitute eligibility guidance for any non-research use.

Can you take CJC-1295/ipamorelin and tesamorelin together?

Tesamorelin is an FDA-approved GHRH analog for HIV-associated lipodystrophy; co-administration with CJC-1295/ipamorelin has not been formally studied in peer-reviewed literature. Both CJC-1295 and tesamorelin bind the GHRH receptor — pharmacological redundancy on the GHRH-R axis is a mechanistic concern, not a studied safety outcome.